PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of gutGutView this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Gut. 1996; 38(Suppl 2): S18–S23.
PMCID: PMC1398038

Epidemiology of hepatitis B infection in the Western Pacific and South East Asia.

Abstract

The Western Pacific and South East Asia regions are the largest and most populous of the six World Health Organisation regions and include more than 40 countries. More than 75% of the world's estimated 350 million carriers are located here. The region has therefore provided many insights into the epidemiology, natural history, and control of hepatitis B infection and has been home to the first national control programmes. Hepatitis B is hyperendemic in most countries of the region, with carrier rates ranging from 5-35% except in Australia, New Zealand, and Japan, where the mean carrier rate is less than 2%. Patterns of infection vary considerably from country to country, city to city, and even village to village, and can change with time. Most infections are acquired early in childhood or in early adult life. A variety of control measures are in place and many countries in the region have introduced widespread or universal childhood immunisation policies with significant success. While it is theoretically possible that hepatitis B infection could be eradicated by universal childhood immunisation, there are several biological and practical issues that make this extremely difficult, suggesting that, for the foreseeable future, control may be a more realisable goal.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • BLUMBERG BS, ALTER HJ, VISNICH S. A "NEW" ANTIGEN IN LEUKEMIA SERA. JAMA. 1965 Feb 15;191:541–546. [PubMed]
  • Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol. 1977 Feb;105(2):94–98. [PubMed]
  • Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981 Nov 21;2(8256):1129–1133. [PubMed]
  • Obata H, Hayashi N, Motoike Y, Hisamitsu T, Okuda H, Kobayashi S, Nishioka K. A prospective study on the development of hepatocellular carcinoma from liver cirrhosis with persistent hepatitis B virus infection. Int J Cancer. 1980 Jun 15;25(6):741–747. [PubMed]
  • Speed BR, Dimitrakakis M, Thoma K, Gust ID. Control of HBV and HDV infection in an isolated Pacific Island: 1. Pattern of infection. J Med Virol. 1989 Sep;29(1):13–19. [PubMed]
  • Zhuang H, Coulepis AG, Zimmet P, Taylor R, Ram P, Banuve S, Gust ID. Seroepidemiology of infection with hepatitis B virus in Fiji. Am J Epidemiol. 1982 Oct;116(4):608–616. [PubMed]
  • Milne A, Allwood GK, Moyes CD, Pearce NE, Lucas CR. Prevalence of hepatitis B infections in a multiracial New Zealand community. N Z Med J. 1985 Jul 10;98(782):529–532. [PubMed]
  • Wan X, Currie B, Miller N, Mathews JD. Acute hepatitis B infection in aboriginal Australians. Aust J Public Health. 1993 Dec;17(4):331–333. [PubMed]
  • Gust ID. Control of hepatitis B in Australia. The case for alternative strategies. Med J Aust. 1992 Jun 15;156(12):819–821. [PubMed]
  • Gust ID, Dimitrakakis M, Zimmet P. Studies on hepatitis B surface antigen and antibody in Nauru. I. Distribution amongst Nauruans. Am J Trop Med Hyg. 1978 Sep;27(5):1030–1036. [PubMed]
  • Tsen YJ, Chang MH, Hsu HY, Lee CY, Sung JL, Chen DS. Seroprevalence of hepatitis B virus infection in children in Taipei, 1989: five years after a mass hepatitis B vaccination program. J Med Virol. 1991 Jun;34(2):96–99. [PubMed]
  • Gust ID, Dimitrakakis M, Bott F, Zimmet P. Studies on hepatitis B surface antigen and antibody in Nauru. II. Distribution amongst Gilbert and Ellice (Tuvalu) islanders. Am J Trop Med Hyg. 1978 Nov;27(6):1206–1209. [PubMed]
  • Gust ID, Lehmann NI, Dimitrakakis M, Zimmet P. Seroepidemiology of infection with hepatitis A and B viruses in an isolated Pacific population. J Infect Dis. 1979 May;139(5):559–563. [PubMed]
  • Gilbert GL. Prevention of vertical transmission of hepatitis B. The place of routine screening in antenatal care, and the case for immunization of infants at risk. Med J Aust. 1984 Aug 18;141(4):213–216. [PubMed]
  • André FE, Zuckerman AJ. Review: protective efficacy of hepatitis B vaccines in neonates. J Med Virol. 1994 Oct;44(2):144–151. [PubMed]
  • Campbell DH, Sargent JW, Plant AJ. The prevalence of markers of infection with hepatitis B virus in a mixed-race Australian community. Med J Aust. 1989 May 1;150(9):489–492. [PubMed]
  • Burgess MA, McIntosh ED, Allars HM, Kenrick KG. Hepatitis B in urban Australian schoolchildren. No evidence of horizontal transmission between high-risk and low-risk groups. Med J Aust. 1993 Sep 6;159(5):315–319. [PubMed]
  • Milne S. Hepatitis B vaccination in New Zealand. Aust J Public Health. 1993 Dec;17(4):398–398. [PubMed]
  • Ruff TA, Gertig DM, Otto BF, Gust ID, Sutanto A, Soewarso TI, Kandun N, Marschner IC, Maynard JE. Lombok Hepatitis B Model Immunization Project: toward universal infant hepatitis B immunization in Indonesia. J Infect Dis. 1995 Feb;171(2):290–296. [PubMed]
  • Wong WC, Tsang KK. A mass hepatitis B vaccination programme in Taiwan: its preparation, results and reasons for uncompleted vaccinations. Vaccine. 1994;12(3):229–234. [PubMed]
  • Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 1989 Sep 9;2(8663):588–591. [PubMed]
  • Kosaka Y, Takase K, Kojima M, Shimizu M, Inoue K, Yoshiba M, Tanaka S, Akahane Y, Okamoto H, Tsuda F, et al. Fulminant hepatitis B: induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. Gastroenterology. 1991 Apr;100(4):1087–1094. [PubMed]
  • Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med. 1991 Jun 13;324(24):1699–1704. [PubMed]
  • Hsu HY, Chang MH, Lee CY, Hsieh KH, Ni YH, Chen PJ, Chen DS. Precore mutant of hepatitis B virus in childhood fulminant hepatitis B: an infrequent association. J Infect Dis. 1995 Apr;171(4):776–781. [PubMed]
  • Laskus T, Persing DH, Nowicki MJ, Mosley JW, Rakela J. Nucleotide sequence analysis of the precore region in patients with fulminant hepatitis B in the United States. Gastroenterology. 1993 Oct;105(4):1173–1178. [PubMed]
  • Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, Chen CL. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983 Nov 12;2(8359):1099–1102. [PubMed]
  • Beasley RP, Hwang LY, Lin CC, Stevens CE, Wang KY, Sun TS, Hsieh FJ, Szmuness W. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial. Lancet. 1981 Aug 22;2(8243):388–393. [PubMed]
  • Beasley RP, Hwang LY, Stevens CE, Lin CC, Hsieh FJ, Wang KY, Sun TS, Szmuness W. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology. 1983 Mar-Apr;3(2):135–141. [PubMed]

Articles from Gut are provided here courtesy of BMJ Group